Madrigal 3196-18 A 52-Week, Phase 3 Open-Label Extension Study, with a Resmetirom (MGL-3196) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension
Clinical Trial Grant
Administered By
Medicine, Gastroenterology
Awarded By
Madrigal Pharmaceuticals, Inc.
Start Date
November 21, 2023
End Date
December 31, 2026
Administered By
Medicine, Gastroenterology
Awarded By
Madrigal Pharmaceuticals, Inc.
Start Date
November 21, 2023
End Date
December 31, 2026